Rheumatoid Arthritis

Patients with rheumatoid arthritis who switched to biologics or triple therapy had a longer time to treatment failure versus augmented oral methotrexate.

The emergence of biosimilars will reduce spending on biologics by 3% through 2027.

Two supplemental biologics license applications granted to golimumab to treat adults with psoriatic arthritis and adults with active ankylosing spondylitis.

Top news of the week from Specialty Pharmacy Times.

Many patients with rheumatoid arthritis feel their employers do not understand their condition.

Spending for adalimumab has tripled from 2012 from $4.5 billion.

Sirukumab is an anti-interleukin-6 monoclonal antibody designed to block the IL-6 pathway in a different way than currently approved IL-6 inhibitors.

Results of the case could alter the future of the biosimilar marketplace.

Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.

Ibuprofen use may result in hypertension for patients with arthritis and cardiovascular risks.

Top news of the week from Specialty Pharmacy Times.

Switching from etanercept to biosimilar was not associated with treatment-emergent adverse events in rheumatoid arthritis.

Patients who received the shingles vaccine before treatment for arthritis with tofacitinib showed robust immune responses.

Live varicella-zoster vaccine is adequately immunogenic in patients with rheumatoid arthritis starting treatment with tofacitinib.

Use of oral contraceptives for 7 or more consecutive years associated with lower risk of rheumatoid arthritis.

Top news of the week from Specialty Pharmacy Times.

Hibernating innate lymphoid cells allows inflammation to persist in rheumatoid arthritis.

Work-related factors, such as noxious airborne agents, may elevate the risk of rheumatoid arthritis.

Novel treatment effective against rheumatoid arthritis also produced a marked improvement in skin lesions caused by atopic dermatitis.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.

If approved, Xeljanz will be the first Janus kinase inhibitor for psoriatic arthritis.

Sirukumab is designed to treat adults with moderately-to-severely active rheumatoid arthritis.

New treatment strategies for rheumatoid arthritis led to a reduction in congestive heart failure and cardiovascular mortality after the year 2000.

Study will compare the pharmacokinetics and clinical outcomes between Humira biosimilar and its reference product in the treatment of moderate-to-severe chronic plaque psoriasis.

The FDA is requesting a new clinical study before evaluating a new drug application for baricitinib, an oral medication for moderate-to-severe rheumatoid arthritis.

Officials with the FDA are requesting a new clinical study before Eli Lilly and Incyte Corporation can resubmit for a new drug application (NDA) for baricitinib, a once-daily oral medication for moderate-to-severe rheumatoid arthritis treatment.

New treatments for inflammatory conditions, cancer, and HIV are on the horizon. 

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

The anticipated action date for drug that treats moderate-to-severe active ulcerative colitis is set for March 2018.